Skip to main navigation Skip to search Skip to main content

I am hiQ—a novel pair of accuracy indices for imputed genotypes

  • the INTEGRAL-ILCCO consortium
  • University of Göttingen
  • University of Toronto
  • Harvard University
  • National Institutes of Health
  • University Health Network
  • University of Copenhagen
  • University of Hawai'i at Mānoa
  • Vanderbilt University
  • University of Oviedo
  • Clalit Health Services
  • University of Liverpool
  • Radboud University Nijmegen
  • National Institute of Occupational Health
  • Provincial Health Services Authority
  • Moffitt Cancer Center
  • Dartmouth College
  • Bellvitge Biomedical Research Institute
  • University of Kentucky
  • Lund University
  • Swedish Medical Group
  • Fred Hutchinson Cancer Research Center
  • University of Utah
  • Newcastle University
  • University of Sheffield
  • University of Salzburg
  • Heidelberg University 
  • Umeå University
  • International Agency for Research on Cancer
  • University of Texas MD Anderson Cancer Center
  • Baylor College of Medicine

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Background: Imputation of untyped markers is a standard tool in genome-wide association studies to close the gap between directly genotyped and other known DNA variants. However, high accuracy with which genotypes are imputed is fundamental. Several accuracy measures have been proposed and some are implemented in imputation software, unfortunately diversely across platforms. In the present paper, we introduce Iam hiQ, an independent pair of accuracy measures that can be applied to dosage files, the output of all imputation software. Iam (imputation accuracy measure) quantifies the average amount of individual-specific versus population-specific genotype information in a linear manner. hiQ (heterogeneity in quantities of dosages) addresses the inter-individual heterogeneity between dosages of a marker across the sample at hand. Results: Applying both measures to a large case–control sample of the International Lung Cancer Consortium (ILCCO), comprising 27,065 individuals, we found meaningful thresholds for Iam and hiQ suitable to classify markers of poor accuracy. We demonstrate how Manhattan-like plots and moving averages of Iam and hiQ can be useful to identify regions enriched with less accurate imputed markers, whereas these regions would by missed when applying the accuracy measure info (implemented in IMPUTE2). Conclusion: We recommend using Iam hiQ additional to other accuracy scores for variant filtering before stepping into the analysis of imputed GWAS data.

Original languageEnglish
Article number50
JournalBMC Bioinformatics
Volume23
Issue number1
DOIs
StatePublished - Dec 2022

Keywords

  • Accuracy measures
  • GWAS
  • Genotype imputation
  • High-throughput genotyping

Fingerprint

Dive into the research topics of 'I am hiQ—a novel pair of accuracy indices for imputed genotypes'. Together they form a unique fingerprint.

Cite this